| Project/Area Number |
18F16420
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 外国 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
井本 浩 鹿児島大学, 医歯学域医学系, 教授 (60274461)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARYAL BIBEK 鹿児島大学, 医学部, 外国人特別研究員
|
|---|
| Project Period (FY) |
2018-04-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2018: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | VEGF / serotonin / HCC / CRC / VWF |
|---|
| Outline of Annual Research Achievements |
Our project is 1) to examine the kinetics of intra-platelet VEGF-A in bevacizumab (Avastin) treated colorectal cancer (CRC) patients, and 2) to study dynamics of various intra-platelet growth factor in patients with Hepatocellular carcinoma (HCC). We also conducted in vitro and ex vivo experiments to investigate the bearing of bevacizumab on the intra-platelet VEGF-A. Following four major results were obtained from this grant.
1. We observed a perioperative exhaustion (depletion) of intra-platelet serotonin concentrations in patients who developed early HCC recurrence and this was able to independently predict HCC recurrence [Aryal et. al, Journal of Cancer (2017)].
2. Platelet-derived growth factor-BB (PDGF-BB) was significantly diminished in patients with cancer recurrence. [Aryal B, et al. Journal of Oncology (2019); article id 1925315].
3. We observed a significant elevation of intra-platelet vWF during liver regeneration; moreover, patients who could not achieve marked rise in post-resection intra-platelet vWF concentration were found to have increased incidence of post-resection liver dysfunction [Aryal B, et al. Under Review (2019)].
4. We performed experiments using an ex vivo and in vitro models to examine the effect of bevacizumab and pegaptanib on IP VEGF-A neutralization, suggesting that the intra-platelet VEGF-A could influence the impact of bevacizumab treatment, as platelets represent a major reservoir of VEGF.
I appreciated this funding and would like to proceed more to accomplish this series of the project.
|
| Research Progress Status |
平成30年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
平成30年度が最終年度であるため、記入しない。
|
